Lifeward Ltd. (LFWD) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, LFWD carries an RQD Score of 31 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 6 / 20. The source cites ROIC of -35% and an FCF yield of 0%. The cash-generation pillar is weak, consistent with reported negative free cash flow in the SEC financials across the periods shown.
• Whale 13F Flow: 4 / 20. Institutional accumulation and options positioning scored poorly. The source provides no detail beyond the pillar score, and the Holders section is empty.
• Insider Conviction: 5 / 20. The pillar reflects SEC Form 4 and Congressional PTR cluster flow. The source contains no itemized insider transactions, so the low score cannot be traced to specific trades.
• Macro Regime Fit: 6 / 20. Beta is 1.0 per market data, with sector sensitivity cited in the rating. The source does not elaborate on the macro drivers.
• Forensic Balance Sheet: 10 / 20. The strongest pillar, reflecting Altman Z 2.5, Piotroski F 4/9, and Debt/Equity 0.5 per the Roarable RQD rating.

For a prospective investor evaluating the stock today, the rating points to a weak operating profile: the company's reported losses, negative free cash flow, and negative ROIC mean the business is not currently self-funding. The forensic balance-sheet score is the one pillar with relative support, but it does not offset weakness in cash generation and institutional or insider signals. A low-priced, small-capitalization stock with these characteristics carries elevated volatility and dilution or financing risk; the source does not state whether financing is planned. Valuation multiples such as P/E are not available in source data, so the equity cannot be assessed on earnings-based valuation. The rating's "Avoid" label reflects the composite of these weak pillars.

Lifeward Ltd. is a NASDAQ-listed issuer in the Health Care sector, within the Industrial Specialties industry, per the profile. The source does not describe its products, customers, or revenue model in detail. The SEC financials show reported revenue of $1.4M in FY 2025, $1.7M in FY 2024, and $0.4M in FY 2023. The news wire references the ReWalk® Personal Exoskeleton, indicating the company's product focus.

Per the SEC financials, the company reported operating and net losses in each period shown, with negative free cash flow throughout. Per market data, the gross margin is 96%, while operating and net margins are each -60%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9, per the Roarable RQD rating. Cash declined from $6.7M in FY 2024 to $2.2M in FY 2025, and Debt/Equity is 0.5 per the rating.

Per the recent news and catalysts section, the most material item is the appointment of Ronen Tsimerman as Principal Financial Officer and Principal Accounting Officer, effective November 1, 2026. A separate headline reports that CFO nominee Rami Aviram declined, with Josh Hexter continuing as interim. Leadership transition in finance is a risk watch item given the pressure on cash. Other items include a headline on sustained home use and patient satisfaction for the ReWalk® Personal Exoskeleton in a peer-reviewed study, and routine market-data pieces from TradingView, Yahoo Finance, and others. All news items are flagged YELLOW and categorized as MARKET WIRE. The Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. A prospective investor should watch for finance-leadership continuity given the interim arrangement referenced in the news wire, and for cash-runway implications given the decline in reported cash.

• What are the company's specific products, customers, and revenue sources beyond the ReWalk® reference?
• What is the company's cash runway and does it plan to raise capital, and on what terms?
• Who will serve as CFO after the Tsimerman appointment and the Aviram declination, and is the interim arrangement stable?
• What is the source of the 96% gross margin alongside -60% operating margin, given revenue scale?
• Why are EPS, debt, and several cash figures unreported, and what is the company's debt structure?